Acción MIDATECH PHARMA PLC
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate
Instrumento Inactivo

Otros idiomas Midatech Pharma PLC Nasdaq

Acciones

US59564R1041

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!
Inscripción 100% Gratuita
European Equities Traded in the US as American Depositary Receipts Sharply Lower in Thursday Trading
Results of Annual General Meeting
European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Tuesday Trading
Twelve month Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis (FAP) to be Presented at Prestigious Biennial InSIGHT 2024 Meeting in Barcelona
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading
Biodexa Pharmaceuticals plc Announces Promising Phase 2 Results for Its Newly In-Liced Drug Erapa for Treating Fam Fam Famic Adenomatous Polyposis
European Equities Traded in US as American Depositary Receipts Rise Friday, Poised to End Week Lower
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading
European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Wednesday Trading
European Equities Traded in the US as American Depositary Receipts Trend Higher Friday, End Week Marginally Lower
Tech Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading
Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises
Sector Update: Health Care Stocks Advance Late Afternoon
Top Midday Gainers
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading
Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa’s Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting
Biodexa Pharmaceuticals PLC Announces Positive Statistically Significant Phase 2 Clinical Trial Results of eRapa? in Familial Adenomatous Polyposis Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción BDRX
  4. Acción
  5. Noticias Midatech Pharma PLC
  6. Otros idiomas